Stoke Therapeutics (NASDAQ:STOK) Short Interest Update

Stoke Therapeutics (NASDAQ:STOK) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totalling 2,500,000 shares, a decrease of 29.6% from the June 30th total of 3,550,000 shares. Approximately 16.0% of the shares of the company are short sold. Based on an average trading volume of 135,200 shares, the short-interest ratio is presently 18.5 days.

STOK stock opened at $25.19 on Friday. Stoke Therapeutics has a twelve month low of $15.82 and a twelve month high of $39.04. The business’s 50-day simple moving average is $24.34 and its 200 day simple moving average is $24.34.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. On average, sell-side analysts predict that Stoke Therapeutics will post -1.52 earnings per share for the current fiscal year.

STOK has been the subject of a number of research reports. Canaccord Genuity restated a “buy” rating and issued a $44.00 target price on shares of Stoke Therapeutics in a research note on Thursday, July 9th. ValuEngine cut shares of Stoke Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Zacks Investment Research cut Stoke Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. BidaskClub raised shares of Stoke Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 18th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $34.83.

In other news, insider Barry Ticho sold 1,365 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $27.39, for a total value of $37,387.35. Following the transaction, the insider now directly owns 131,147 shares in the company, valued at approximately $3,592,116.33. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Huw M. Nash sold 2,107 shares of Stoke Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $27.18, for a total transaction of $57,268.26. Following the completion of the transaction, the chief operating officer now directly owns 2,107 shares of the company’s stock, valued at $57,268.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,526 shares of company stock worth $1,023,872. Corporate insiders own 54.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Nuveen Asset Management LLC raised its position in Stoke Therapeutics by 302.2% in the first quarter. Nuveen Asset Management LLC now owns 86,110 shares of the company’s stock worth $1,972,000 after purchasing an additional 64,698 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Stoke Therapeutics by 55.2% during the 1st quarter. Geode Capital Management LLC now owns 185,856 shares of the company’s stock worth $4,256,000 after buying an additional 66,139 shares during the period. Alliancebernstein L.P. bought a new stake in Stoke Therapeutics in the first quarter valued at $396,000. BlackRock Inc. raised its stake in Stoke Therapeutics by 49.1% during the first quarter. BlackRock Inc. now owns 1,370,786 shares of the company’s stock worth $31,391,000 after acquiring an additional 451,363 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Stoke Therapeutics in the 1st quarter valued at $4,178,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Further Reading: What is the Euro STOXX 50 Index?

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.